Last Updated: October 22, 2026
Bakuchiol's best-known comparison with retinol enrolled just 44 people. That makes it worth investigating, not a universal substitute. If you have seen it described as irritation-free, pregnancy-safe, or identical to retinol, the research supports a more careful account.
This guide separates three questions: what bakuchiol does in laboratory models, what small human studies have measured, and what those findings can tell you about a particular product.
Medical disclaimer: This is general ingredient education, not medical advice or a treatment plan for acne, rosacea, or another diagnosed condition. If you are pregnant, trying to conceive, breastfeeding, or receiving dermatologic treatment, ask a qualified clinician to review your complete routine before adding an active. No product is certified as pregnancy-safe by this article.
What is bakuchiol, and is it a retinoid?
Tier 3 for the laboratory mechanism: Bakuchiol is a plant-derived compound structurally distinct from retinoids. Chaudhuri and Bojanowski (2014), International Journal of Cosmetic Science, reported overlapping gene-expression changes with retinol in laboratory skin models and investigated collagen-related effects. These findings help explain why bakuchiol is called a retinol alternative, but they do not mean it is vitamin A or works identically to a retinoid. PMID 24471735.
A laboratory signal is not the same as a visible clinical benefit. The same publication included a small clinical case study, but that does not turn every mechanistic claim into a randomized human finding. The useful distinction is between a plausible mechanism and a benefit demonstrated under specific treatment conditions. Chaudhuri and Bojanowski (2014), International Journal of Cosmetic Science, PMID 24471735.
The clinical evidence: what the retinol comparison measured
The 12-week randomized trial
Tier 2, early clinical evidence: Dhaliwal et al. (2019), British Journal of Dermatology, randomized 44 participants to 0.5% bakuchiol cream twice daily or 0.5% retinol cream once daily for 12 weeks. Both groups showed reductions in wrinkle surface area and hyperpigmentation compared with baseline. The investigators found no statistically significant difference between groups for these measured outcomes. PMID 29947134.
Retinol users reported more scaling and stinging. That is a specific tolerability finding under the trial conditions, not proof that bakuchiol never causes irritation, that it is appropriate for every sensitive-skin condition, or that a finished product containing it cannot cause a reaction. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134.
Why “no significant difference” does not establish equivalence
The study was small, lasted 12 weeks, and used different application frequencies. Failure to detect a difference does not establish that the treatments are interchangeable across concentrations, formulations, outcomes, or longer-term use. It also does not establish that bakuchiol works faster or slower than every retinoid. The defensible claim is narrower: both tested regimens improved selected photoaging measures in this trial. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134.
The wider literature still has limitations
Tier 2 overall, with substantial uncertainty: Fanning et al. (2024), Journal of Drugs in Dermatology, reviewed 15 human trials identified through an August 2022 search. Twelve were unblinded, open-label studies without a control group, and ten tested combination therapies. The authors highlighted high risk of bias, inconsistent methods, and difficulty isolating bakuchiol's contribution. Their review supports further research, not a blanket claim that all bakuchiol products match retinoids. PMID 38564402.
Bakuchiol vs. retinol: the comparison that matters
- Identity: Bakuchiol is not a retinoid. Laboratory overlap with retinol does not establish identical action. Chaudhuri and Bojanowski (2014), International Journal of Cosmetic Science, PMID 24471735.
- Visible results: One small randomized comparison supports early promise for wrinkles and hyperpigmentation under its tested regimens. It does not establish universal equivalence. Tier 2. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134.
- Tolerability: More scaling and stinging occurred in the retinol arm. That does not establish zero irritation with bakuchiol. Tier 2. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134.
- What remains unanswered: The cited trial cannot determine pregnancy safety, performance of rinse-off products, or how every multi-active formula compares with retinol. Those claims require separate evidence, not an upgraded interpretation of the same study.
Pregnancy and breastfeeding: not established as safe
Pregnancy safety: unestablished, not a positive evidence tier. The photoaging trial did not establish reproductive or fetal safety. A non-retinoid structure and a favorable short-term tolerability finding cannot fill that gap. Do not interpret “plant-derived” or “natural retinol” as pregnancy clearance. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134; Chaudhuri and Bojanowski (2014), International Journal of Cosmetic Science, PMID 24471735.
Clinical precaution, rather than a randomized safety result: Putra et al. (2022), Journal of Clinical and Aesthetic Dermatology, recommend avoiding topical retinoids during pregnancy because of the uncertain risk-benefit balance. That guidance does not establish bakuchiol as a validated replacement, nor should pregnancy and breastfeeding be treated as interchangeable exposure questions. Ask your clinician about the full formula and your circumstances. PMID 35309882.
For the detailed distinction, read what the bakuchiol trial does not establish about pregnancy and our related bakuchiol pregnancy evidence review. Historical wording in a URL is not a safety recommendation.
How to evaluate a bakuchiol product
Check the format before borrowing a study's results
Our Brightening Vitamin C & Bakuchiol Soap Bar is a rinse-off cleanser. It is not the leave-on 0.5% cream tested in the randomized study. Ingredient presence alone does not establish equivalent exposure, wrinkle improvement, or pigmentation results. Finished-product efficacy: not established by the cited trial. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134.
Check whether it contains a retinoid too
The Heimish RX Retinol Bakuchiol 1% Booster Oil is listed as containing retinol and bakuchiol. It is not a retinoid-free option. The product name does not establish the concentration of each individual ingredient, and the addition of bakuchiol does not cancel pregnancy precautions for a retinol-containing formula. Putra et al. (2022), Journal of Clinical and Aesthetic Dermatology, PMID 35309882.
A practical introduction protocol
- Define the goal. Cosmetic texture concerns and a diagnosed condition are different decisions; get medical advice for the latter.
- Read the complete formula and directions. Verify whether it is rinse-off or leave-on and whether retinol is included.
- Do not copy a research schedule blindly. Twice-daily 0.5% cream was a trial regimen, not a universal instruction for unrelated products.
- Keep changes simple. Introduce one new product at a time according to its label rather than assuming compatibility with every other active. Stop and seek advice if a reaction occurs.
- Use a realistic checkpoint. The main comparison assessed outcomes over 12 weeks; it does not guarantee your result at that time.
The research basis for that checkpoint is Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134. For broader context, explore our bakuchiol-versus-retinol evidence comparison and retinol and bakuchiol routine page. These resources are background reading, not pregnancy clearance.
Commercial disclosure: Veracil sells the linked products. The cards below identify different product formats, not clinically validated equivalents to the trial cream or pregnancy recommendations. Evidence about an ingredient is not proof of a finished formula's performance.
What bakuchiol does not establish
It is not a demonstrated cure for acne or rosacea on the basis of the photoaging trial. It is not established as irritation-free, equivalent to every retinoid, or safe during pregnancy. Laboratory gene-expression findings do not guarantee visible collagen-related improvements in every commercial product. These boundaries follow the limited scope of Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134, and the methodological concerns raised by Fanning et al. (2024), Journal of Drugs in Dermatology, PMID 38564402.
Verdict: promising, but not interchangeable with retinol
Preliminary Confirm, Tier 2, for selected photoaging outcomes: Bakuchiol deserves consideration as a cosmetic ingredient with early human findings for wrinkles and hyperpigmentation. The 12-week comparison is encouraging, but stronger replication and better-controlled studies are needed before making broad equivalence claims. Dhaliwal et al. (2019), British Journal of Dermatology, PMID 29947134; Fanning et al. (2024), Journal of Drugs in Dermatology, PMID 38564402.
Inconclusive for pregnancy safety: Cosmetic efficacy and reproductive safety are separate questions. Choose by the evidence for the intended use and the complete formula, not by the phrase “natural retinol.”
0 comments